Loading clinical trials...
Loading clinical trials...
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Technical University of Munich
Collaborators
NCT07222137 · Diabetes Mellitus, Type 1
NCT06807190 · Diabetes Mellitus, Type 1
NCT07160816 · Diabetes Mellitus, Type 1
NCT07478211 · Diabetes Mellitus, Type 1, Energy Metabolism
NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, and more
Medical University of Vienna, Dept. of Pediatric and Adolescent Medicine, Waehringer Gürtel 18-20, 1090 Vienna, Austria
Vienna
University Hospitals Leuven, Faculty of Medicine, Catholic University of Leuven
Leuven
Klinikum rechts der Isar of Technical University Munich and Institute for Diabetes Research, Helmholtz Munich
Munich, Bavaria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions